Anastrozole label

Anastrozole

Anastrozole Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

• kidney disease • a magnesium-restricted diet • stomach pain, nausea, or vomiting • a sudden change in bowel habits that lasts over 14 days taking a prescription drug. This product may interact with certain prescription drugs. • you have rectal bleeding or no bowel movement after using this product. These could be signs of a serious condition. • you need to use a laxative for more than 1 week ask a health professional before use.

Ask a doctor before use if you have

Ask a doctor or pharmacist before use if you are

Stop use and ask a doctor if

If pregnant or breast-feeding,

In case of overdose, get medical help or contact a Poison Control Center right away. Keep out of reach of children.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

  • relieves occasional constipation (irregularity)
  • generally produces bowel movement in 1/2 to 6 hours
Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

There are no additional details available for this product.

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Anastrozole Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Anastrozole Manufacturers

  • Northwind Pharmaceuticals, Llc
    Anastrozole | Tya Pharmaceuticals
    No Recall

    Anastrozole | Tya Pharmaceuticals

    Anastrozole | Tya Pharmaceuticals

    • shake well before use • do not exceed the maximum recommended daily dose in a 24 hour period • dose may be taken once a day preferably at bedtime, in divided doses, or as directed by a doctor • drink a full glass (8 oz) of liquid with each dose adults and children 12 years and older: 2 to 4 tablespoonfuls children 6 to 11 years: 1 to 2 tablespoonfuls children under 6 years: ask a doctor









  • Cypress Pharmaceutical, Inc.
    Anastrozole | Cypress Pharmaceutical, Inc.
    No Recall

    Anastrozole | Cypress Pharmaceutical, Inc.

    Anastrozole | Cypress Pharmaceutical, Inc.

    2.1 Recommended Dose

    The dose of Anastrozole is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Anastrozole should be continued until tumor progression. Anastrozole can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial Anastrozole was administered for five years. [see Clinical Studies (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Breckenridge Pharmaceutical, Inc.
    Anastrozole | Breckenridge Pharmaceutical, Inc.
    No Recall

    Anastrozole | Breckenridge Pharmaceutical, Inc.

    Anastrozole | Breckenridge Pharmaceutical, Inc.
    2.1 Recommended Dose
    The dose of anastrozole tablets are one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years. [see Clinical Studies (14.1)]
    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)] 2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Kaiser Foundation Hospitals
    Anastrozole | Kaiser Foundation Hospitals
    No Recall

    Anastrozole | Kaiser Foundation Hospitals

    Anastrozole | Kaiser Foundation Hospitals
    2.1 Recommended Dose
    The dose of anastrozole tablets are one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years. [see Clinical Studies (14.1)]
    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)] 2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Udl Laboratories, Inc.
    Anastrozole | Udl Laboratories, Inc.
    No Recall

    Anastrozole | Udl Laboratories, Inc.

    Anastrozole | Udl Laboratories, Inc.
    2.1 Recommended Dose

    The dose of anastrozole tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for 5 years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild to moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Pack Pharmaceuticals, Llc
    Anastrozole | Pack Pharmaceuticals, Llc
    No Recall

    Anastrozole | Pack Pharmaceuticals, Llc

    Anastrozole | Pack Pharmaceuticals, Llc
    2.1 Recommended Dose

    The dose of anastrozole tablets are one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years. [see Clinical Studies (14.1)]  

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)] 

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment. [See Use in Specific Populations (8.7)]

  • Major Pharmaceuticals
    Anastrozole | Major Pharmaceuticals
    No Recall

    Anastrozole | Major Pharmaceuticals

    Anastrozole | Major Pharmaceuticals


    2. DOSAGE AND ADMINISTRATION

    2.1. Recommended Dose
        The dose of anastrozole tablets are one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.
        For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years. [see Clinical Studies (14.1)]
        No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2. Patients with Hepatic Impairment
        No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Rebel Distributors Corp
    Anastrozole | Rebel Distributors Corp
    No Recall

    Anastrozole | Rebel Distributors Corp

    Anastrozole | Rebel Distributors Corp
    2.1. Recommended Dose

    The dose of anastrozole tablets are one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.
        For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years. [see Clinical Studies (14.1)]
        No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2. Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]


  • Synthon Pharmaceuticals, Inc.
    Anastrozole | Synthon Pharmaceuticals, Inc.
    No Recall

    Anastrozole | Synthon Pharmaceuticals, Inc.

    Anastrozole | Synthon Pharmaceuticals, Inc.
    2.1 Recommended Dose

    The dose of Anastrozole Tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Anastrozole Tablets should be continued until tumor progression. Anastrozole Tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial Anastrozole Tablets were administered for five years. [see Clinical Studies (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole Tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Kremers Urban Pharmaceuticals Inc.
    Anastrozole | Kremers Urban Pharmaceuticals Inc.
    No Recall

    Anastrozole | Kremers Urban Pharmaceuticals Inc.

    Anastrozole | Kremers Urban Pharmaceuticals Inc.
    2.1 Recommended Dose

    The dose of Anastrozole Tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Anastrozole Tablets should be continued until tumor progression. Anastrozole Tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial Anastrozole Tablets were administered for five years. [see Clinical Studies (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole Tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Ascend Laboratories, Llc
    Anastrozole | Ascend Laboratories, Llc
    No Recall

    Anastrozole | Ascend Laboratories, Llc

    Anastrozole | Ascend Laboratories, Llc


    2. DOSAGE AND ADMINISTRATION

    2.1. Recommended Dose
        The dose of anastrozole tablets are one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.
        For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years. [see Clinical Studies (14.1)]
        No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2. Patients with Hepatic Impairment
        No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Ascend Laboratories, Llc
    Anastrozole | Ascend Laboratories, Llc
    No Recall

    Anastrozole | Ascend Laboratories, Llc

    Anastrozole | Ascend Laboratories, Llc


    2. DOSAGE AND ADMINISTRATION

    2.1. Recommended Dose
        The dose of anastrozole tablets are one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.
        For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years. [see Clinical Studies (14.1)]
        No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2. Patients with Hepatic Impairment
        No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Sun Pharmaceutical Industries Limited
    Anastrozole | Sun Pharmaceutical Industries Limited
    No Recall

    Anastrozole | Sun Pharmaceutical Industries Limited

    Anastrozole | Sun Pharmaceutical Industries Limited
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole tablet was administered for five years. [see Clinical Studies (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Boscogen, Inc.
    Anastrozole | Boscogen, Inc.
    No Recall

    Anastrozole | Boscogen, Inc.

    Anastrozole | Boscogen, Inc.

    2.1 Recommended Dose

    The dose of Anastrozole is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Anastrozole should be continued until tumor progression. Anastrozole can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial Anastrozole was administered for five years. [see Clinical Studies (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • App Pharmaceuticals, Llc
    Anastrozole | App Pharmaceuticals, Llc
    No Recall

    Anastrozole | App Pharmaceuticals, Llc

    Anastrozole | App Pharmaceuticals, Llc
    2.1 Recommended Dose
          The dose of anastrozole is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets 1 mg should be continued until tumor progression. Anastrozole tablets 1 mg can be taken with or without food.
     
          For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole tablets 1 mg were administered for five years [see Clinical Studies (14.1)].
           No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)]. 2.2 Patients with Hepatic Impairment
          No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].
  • Cadila Healthcare Limited
    Anastrozole | Cadila Healthcare Limited
    No Recall

    Anastrozole | Cadila Healthcare Limited

    Anastrozole | Cadila Healthcare Limited
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablet should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years [see CLINICAL STUDIES (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see USE IN SPECIFIC POPULATIONS (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment [see USE IN SPECIFIC POPULATIONS (8.7)].

  • Dr. Reddy’s Laboratories Limited
    Anastrozole | Dr. Reddy's Laboratories Limited
    No Recall

    Anastrozole | Dr. Reddy's Laboratories Limited

    Anastrozole | Dr. Reddy's Laboratories Limited

    2.1 Recommended Dose

    The dose of anastrozole is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole should be continued until tumor progression. Anastrozole can be taken with or without food.  

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole was administered for five years. [see Clinical Studies (14.1)]  

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [seeUse in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Rebel Distributors Corp
    Anastrozole | Rebel Distributors Corp
    No Recall

    Anastrozole | Rebel Distributors Corp

    Anastrozole | Rebel Distributors Corp
    2.1 Recommended Dose

    The dose of anastrozole tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole was administered for five years. [see Clinical Studies (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Roxane Laboratories, Inc.
    Anastrozole | Roxane Laboratories, Inc.
    No Recall

    Anastrozole | Roxane Laboratories, Inc.

    Anastrozole | Roxane Laboratories, Inc.
    2.1 Recommended Dose

    The dose of anastrozole is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole should be continued until tumor progression. Anastrozole can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole was administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Pd-rx Pharmaceuticals, Inc.
    Anastrozole | Genesis Pharmaceutical, Inc.
    No Recall

    Anastrozole | Genesis Pharmaceutical, Inc.

    Anastrozole | Genesis Pharmaceutical, Inc.
    Apply liberally 15  minutes before sun exposure Reapply: after 40 minutes of swimming or sweating immediately after towel drying at least every 2 hours Children under 6 months: Ask a doctor Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m. - 2 p.m. wear long-sleeve shirts, pants, hats, and sunglasses
  • Golden State Medical Supply, Inc.
    Anastrozole | Golden State Medical Supply, Inc.
    No Recall

    Anastrozole | Golden State Medical Supply, Inc.

    Anastrozole | Golden State Medical Supply, Inc.
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole tablet was administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Dispensing Solutions, Inc.
    Anastrozole | Dispensing Solutions, Inc.
    No Recall

    Anastrozole | Dispensing Solutions, Inc.

    Anastrozole | Dispensing Solutions, Inc.
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole was administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Major Pharmaceuticals
    Anastrozole | Major Pharmaceuticals
    No Recall

    Anastrozole | Major Pharmaceuticals

    Anastrozole | Major Pharmaceuticals
    2.1 Recommended Dose

    The dose of anastrozole tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole was administered for five years. [see Clinical Studies (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations (8.7)]

  • Kadmon Pharmaceuticals, Llc
    Anastrozole | Kadmon Pharmaceuticals, Llc
    No Recall

    Anastrozole | Kadmon Pharmaceuticals, Llc

    Anastrozole | Kadmon Pharmaceuticals, Llc
    2.1 Recommended Dose

    The dose of anastrozole tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets was administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • American Health Packaging
    Anastrozole | American Health Packaging
    No Recall

    Anastrozole | American Health Packaging

    Anastrozole | American Health Packaging
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablet should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years [see CLINICAL STUDIES (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see USE IN SPECIFIC POPULATIONS (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment [see USE IN SPECIFIC POPULATIONS (8.7)].

  • Zydus Pharmaceuticals (Usa) Inc.
    Anastrozole | Zydus Pharmaceuticals (usa) Inc.
    No Recall

    Anastrozole | Zydus Pharmaceuticals (usa) Inc.

    Anastrozole | Zydus Pharmaceuticals (usa) Inc.
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablet should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years [see CLINICAL STUDIES (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see USE IN SPECIFIC POPULATIONS (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment [see USE IN SPECIFIC POPULATIONS (8.7)].

  • Bluepoint Laboratories
    Anastrozole | Bluepoint Laboratories
    No Recall

    Anastrozole | Bluepoint Laboratories

    Anastrozole | Bluepoint Laboratories
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablet should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years [see CLINICAL STUDIES (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see USE IN SPECIFIC POPULATIONS (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment [see USE IN SPECIFIC POPULATIONS (8.7)].

  • Proficient Rx Lp
    Anastrozole | Proficient Rx Lp
    No Recall

    Anastrozole | Proficient Rx Lp

    Anastrozole | Proficient Rx Lp
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole was administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Mylan Pharmaceuticals Inc.
    Anastrozole | Mylan Pharmaceuticals Inc.
    No Recall

    Anastrozole | Mylan Pharmaceuticals Inc.

    Anastrozole | Mylan Pharmaceuticals Inc.
    2.1 Recommended Dose

    The dose of anastrozole tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole tablets were administered for 5 years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild to moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Apotex Corp.
    Anastrozole | Apotex Corp.
    No Recall

    Anastrozole | Apotex Corp.

    Anastrozole | Apotex Corp.

    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole tablet was administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Teva Pharmaceuticals Usa Inc
    Anastrozole | Teva Pharmaceuticals Usa Inc
    No Recall

    Anastrozole | Teva Pharmaceuticals Usa Inc

    Anastrozole | Teva Pharmaceuticals Usa Inc
    2.1 Recommended Dose

    The dose of anastrozole tablets is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole tablets were administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients With Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablets have not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Bryant Ranch Prepack
    Anastrozole | Bryant Ranch Prepack
    No Recall

    Anastrozole | Bryant Ranch Prepack

    Anastrozole | Bryant Ranch Prepack
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole was administered for five years [see Clinical Studies (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].

  • Sandoz Inc
    Anastrozole | Sandoz Inc
    No Recall

    Anastrozole | Sandoz Inc

    Anastrozole | Sandoz Inc
    2.1 Recommended Dose

    The dose of anastrozole is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole should be continued until tumor progression. Anastrozole can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole was administered for five years. [see CLINICAL STUDIES (14.1)]

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see USE IN SPECIFIC POPULATIONS (8.6)]

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment. [see USE IN SPECIFIC POPULATIONS (8.7)]

  • Accord Healthcare Inc.
    Anastrozole | Accord Healthcare Inc.
    No Recall

    Anastrozole | Accord Healthcare Inc.

    Anastrozole | Accord Healthcare Inc.
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablets should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, anastrozole was administered for five years [see Clinical Studies ( 14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see Use in Specific Populations ( 8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole has not been studied in patients with severe hepatic impairment [see Use in Specific Populations ( 8.7)].

  • American Health Packaging
    Anastrozole | American Health Packaging
    No Recall

    Anastrozole | American Health Packaging

    Anastrozole | American Health Packaging
    2.1 Recommended Dose

    The dose of anastrozole tablet is one 1 mg tablet taken once a day. For patients with advanced breast cancer, anastrozole tablet should be continued until tumor progression. Anastrozole tablets can be taken with or without food.

    For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial anastrozole tablets were administered for five years [see CLINICAL STUDIES (14.1)].

    No dosage adjustment is necessary for patients with renal impairment or for elderly patients [see USE IN SPECIFIC POPULATIONS (8.6)].

    2.2 Patients with Hepatic Impairment

    No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole tablet has not been studied in patients with severe hepatic impairment [see USE IN SPECIFIC POPULATIONS (8.7)].

Login To Your Free Account